Core Insights - The NHS-Galleri trial demonstrated a significant reduction in Stage IV cancer diagnoses and an increase in the detection of Stage I and II cancers, although the primary endpoint of statistically significant reduction in Stage III-IV cancers was not met [1][2] Group 1: Trial Results - The Galleri test led to a substantial reduction in cancers detected through emergency presentations, which are linked to higher mortality and healthcare costs [1] - There was a notable increase in the absolute number of Stage I-II cancers among 12 pre-specified deadly cancer types in the intervention group [1] - The overall cancer detection rate improved four-fold when Galleri was added to standard care screening compared to standard care alone for breast, colorectal, cervical, and high-risk lung cancers [1] - A clinically meaningful reduction in Stage IV diagnoses was observed, with over a 20% decrease in the second and third rounds of sequential screening for the specified group of cancers [1][2] Group 2: Trial Design and Objectives - The NHS-Galleri trial is the largest randomized controlled trial assessing a multi-cancer early detection test, involving over 142,000 participants aged 50 to 77 [2] - The primary objective was to show a reduction in late-stage (III-IV) cancers in those receiving the Galleri test compared to those who did not [2] - Secondary objectives included evaluating the performance of the Galleri test, safety, and healthcare resource utilization [2] Group 3: Company and Product Information - GRAIL, Inc. focuses on early cancer detection using next-generation sequencing and machine learning to identify multiple cancer types at earlier stages [2] - The Galleri test can detect over 50 types of cancer through a simple blood draw, significantly increasing the number of cancers detected when used alongside standard screenings [2] - The test is recommended for adults aged 50 or older with an elevated risk for cancer and has the lowest false positive rate among multi-cancer early detection tests [2]

measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock- based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in accordance with GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater tran ...

Synopsys Appoints Former Deloitte Executive Peter Shimer to Board of Directors and Announces Board Transitions [Accessibility Statement] Skip NavigationSUNNYVALE, Calif., Feb. 19, 2026 /PRNewswire/ -- [Synopsys], Inc. (NASDAQ: SNPS) today announced the appointment of Peter A. Shimer to its board of directors. Shimer brings four decades of experience at international public accounting firm Deloitte where he held numerous executive roles, including serving as its interim chief executive officer (CEO). During ...

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of JFB Construction Holdings (NASDAQ: JFB) [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- Class Action Attorney [Juan Monteverde] with [Monteverde & Associates PC](the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York Ci ...

GoDaddy ANS Integrates with Salesforce's MuleSoft Agent Fabric [Accessibility Statement] Skip NavigationThe solution helps organizations discover AI agents and confirm identity to reduce the risk of spoofed toolsTEMPE, Ariz., Feb. 19, 2026 /PRNewswire/ -- GoDaddy (NYSE: GDDY) today announced an integration with Salesforce's MuleSoft Agent Fabric that helps companies of all sizes discover AI agents and verify their identity. This helps prevent rogue agents from interacting with business systems and sensitive ...

Group 1 - The law firm Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. related to a federal securities class action due to alleged violations of federal securities laws [1] - The complaint alleges that REGENXBIO and its executives made false or misleading statements and failed to disclose material adverse facts regarding the efficacy and safety of its RGX-111 trial study [1] - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 investigational gene therapy for MPS I after a case of neoplasm was reported in a participant [1] - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the clinical studies [1] - Following the FDA's announcement, REGENXBIO's stock price fell by $2.40 per share, or 17.9%, closing at $11.01 per share [1] Group 2 - The deadline for investors to seek the role of lead plaintiff in the class action is April 14, 2026 [1] - Any member of the putative class can move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1] - Faruqi & Faruqi encourages individuals with information regarding REGENXBIO's conduct to contact the firm, including whistleblowers and former employees [1]

Warner Bros. Discovery to Report Fourth Quarter and Full Year 2025 Results on Thursday, February 26 [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- Warner Bros. Discovery, Inc. (the "Company") (Nasdaq: WBD) today announced that it will report its fourth quarter and full year 2025 results on Thursday, February 26, 2026 before the market opens. Links to the live webcast of the conference call as well as the earnings materials will be available in the "Investor Relations" secti ...

Chubb Appoints Scott Henck Global Chief Actuary [Accessibility Statement] Skip NavigationCynthia Bentley promoted to succeed Henck as North America Chief Actuary; Paul O'Connell to RetireZURICH, Feb. 19, 2026 /PRNewswire/ -- Chubb Limited (NYSE: CB) today announced that Scott Henck, Executive Vice President and Chief Actuary, North America, has been appointed Senior Vice President, Chubb Group and Chief Actuary. He succeeds Paul O'Connell, who is retiring after a 40-year career in the property and casualty ...

 Mission in the 'Convoy' Campaign[Second mission in the Jeep® brand's Gladiator "Convoy" campaign, following Shadow Ops Heritage-theme, two-tone execution inspired by Jeep brand...]### Jeep® Brand's 'Billy Goes to the River' Takes No. 1 Automotive Spot on YouTube AdBlitz Leaderboard["Billy Goes to the River" was named the top automotive performer for YouTube AdBlitz 2026, with the commercial rising to the top based on a...][More Releases From This Source]## Explore[Automotive][General Sports][Sporting Even ...

Republic Power Group Limited Announces 1-For-20 Reverse Share Split [Accessibility Statement] Skip NavigationSINGAPORE, Feb. 19, 2026 /PRNewswire/ -- Republic Power Group Limited (NASDAQ: RPGL), today announced that it will effect a reverse share split of its Class A ordinary shares, par value $0.000625 per share (the "Class A Ordinary Shares") and Class B ordinary shares, par value $0.000625 per share (the "Class B Ordinary Shares"), at a ratio of 1-for-20, to be effective at the open of business on Februa ...